SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+18.51%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$447M
AUM Growth
+$447M
(+0.78%)
Cap. Flow
+$10.3M
Cap. Flow
% of AUM
2.3%
Top 10 Holdings %
Top 10 Hldgs %
48.85%
Holding
81
New
11
Increased
34
Reduced
11
Closed
21
Top Buys
| 1 |
Pliant Therapeutics
PLRX
|
$17.3M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
$11.3M |
| 3 |
Scholar Rock
SRRK
|
$7.92M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$7.76M |
| 5 |
Ascendis Pharma
ASND
|
$6.4M |
Top Sells
| 1 |
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
|
$25.7M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$9.84M |
| 3 |
Protagonist Therapeutics
PTGX
|
$6.6M |
| 4 |
Sarepta Therapeutics
SRPT
|
$6.4M |
| 5 |
ADC Therapeutics
ADCT
|
$5.65M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Biodesix
BDSX
$65.8M
| $6.63M | 1.45% |
4,332,281
+771,187
| +22% | +$1.18M |
|
27
Gossamer Bio
GOSS
$596M
| $5.58M | 1.22% |
6,171,847
+526,495
| +9% | +$476K |
|
28
Praxis Precision Medicines
PRAX
$969M
| $5.58M | 1.22% |
72,516
+5,471
| +8% | +$421K |
|
|
BBOT
29
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$697M
| $5.39M | 1.18% |
513,369
| – | – |
|
30
Ultragenyx Pharmaceutical
RARE
$2.99B
| $5.23M | 1.14% |
+124,388
| New | +$5.23M |
|
31
KalVista Pharmaceuticals
KALV
$708M
| $5.19M | 1.13% |
612,173
+37,615
| +7% | +$319K |
|
32
Travere Therapeutics
TVTX
$1.62B
| $4.83M | 1.06% |
+277,365
| New | +$4.83M |
|
33
C4 Therapeutics
CCCC
$183M
| $4.4M | 0.96% |
1,221,131
+73,240
| +6% | +$264K |
|
34
Structure Therapeutics
GPCR
$1.15B
| $4.13M | 0.9% |
152,395
+81,879
| +116% | +$2.22M |
|
35
Tarsus Pharmaceuticals
TARS
$2.51B
| $3.65M | 0.8% |
65,955
+25,955
| +65% | +$1.44M |
|
36
Incyte
INCY
$17B
| $3.38M | 0.74% |
+49,000
| New | +$3.38M |
|
37
Vaxcyte
PCVX
$4.04B
| $3.34M | 0.73% |
40,788
-19,712
| -33% | -$1.61M |
|
38
Geron
GERN
$938M
| $3.26M | 0.71% |
920,022
-881,539
| -49% | -$3.12M |
|
39
Trevi Therapeutics
TRVI
$889M
| $3.03M | 0.66% |
734,234
+251,659
| +52% | +$1.04M |
|
40
Compugen
CGEN
$134M
| $2.49M | 0.54% |
1,624,377
+123,264
| +8% | +$189K |
|
41
Cerus
CERS
$245M
| $2.44M | 0.53% |
1,587,228
+91,899
| +6% | +$142K |
|
|
ABVX
42
Abivax
ABVX
$6.1B
| $2.09M | 0.46% |
285,120
-176,540
| -38% | -$1.29M |
|
43
Unicycive Therapeutics
UNCY
$74.9M
| $1.97M | 0.43% |
2,486,709
-1,513,291
| -38% | -$1.2M |
|
44
Viridian Therapeutics
VRDN
$1.55B
| $1.92M | 0.42% |
+100,000
| New | +$1.92M |
|
45
Delcath Systems
DCTH
$391M
| $1.87M | 0.41% |
+155,325
| New | +$1.87M |
|
46
uniQure
QURE
$907M
| $1.77M | 0.39% |
+100,000
| New | +$1.77M |
|
47
Modular Medical
MODD
$39.4M
| $1.74M | 0.38% |
1,272,015
-167,985
| -12% | -$230K |
|
48
KALA BIO
KALA
$83M
| $1.6M | 0.35% |
+231,070
| New | +$1.6M |
|
49
Olema Pharmaceuticals
OLMA
$406M
| $1.36M | 0.3% |
233,281
-221,801
| -49% | -$1.29M |
|
50
Gilead Sciences
GILD
$139B
| $924K | 0.2% |
+10,000
| New | +$924K |
|